Certainly, further experiments, especially in vivo, can help to gain further insight into the deeper mechanisms, but at the preclinical level, our study is the first attempt to investigate the suitability of cancer immunotherapy of CIK cells together with HSP90 in Burkitt’s lymphoma. The gene discussed is HSP90AA1; the disease is Burkitt lymphoma.